close
close

Critical Comparison: CERO Therapeutics (NASDAQ:CERO) & Trinity Capital (NASDAQ:TRIN)


CERo Therapeutics (NASDAQ:CERO – Get Free Report) and Trinity Capital (NASDAQ:TRIN – Get Free Report) are both small medical companies, but which is the superior sector? We will compare the two companies based on the strength of their earnings, analyst recommendations, dividends, risk, institutional ownership, profitability and valuation.

Profitability

This table compares the net margins, return on equity, and return on assets of CERo Therapeutics and Trinity Capital.

Net margins Return on equity Return on assets
CERO Therapeutics N/A N/A N/A
Trinity capital 36.12% 16.73% 7.57%

Institutional and insider ownership

29.6% of CERo Therapeutics’ shares are held by institutional investors. By comparison, 24.6% of Trinity Capital’s shares are held by institutional investors. 15.8% of CERo Therapeutics shares are owned by company insiders. By comparison, 6.4% of Trinity Capital’s shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Volatility and risk

CERo Therapeutics has a beta of -0.08, indicating that its stock price is 108% less volatile than the S&P 500. In comparison, Trinity Capital has a beta of 0.6, indicating that its stock price is 40% less volatile than the S&P 500.

Valuation and profit

This table compares the revenue, earnings per share (EPS) and valuation of CERo Therapeutics and Trinity Capital.

Gross income Price/sales ratio Net income Profit per share Price/earnings ratio
CERO Therapeutics N/A N/A N/A N/A N/A
Trinity capital $181.85 million 4.04 $76.89 million $1.61 9.21

Trinity Capital has higher earnings and revenue than CERo Therapeutics.

Analyst Ratings

This is a summary of the current recommendations for CERo Therapeutics and Trinity Capital, as provided by MarketBeat.

Sales reviews Hold reviews Buy reviews Strong Buy Ratings Review score
CERO Therapeutics 0 0 0 0 N/A
Trinity capital 0 1 5 0 2.83

Trinity Capital has a consensus price target of $15.50, indicating a potential upside of 4.52%. Given Trinity Capital’s higher potential upside, analysts clearly believe Trinity Capital is more favorable than CERo Therapeutics.

Resume

Trinity Capital beats CERo Therapeutics on seven of the nine factors comparing the two stocks.

About CERo Therapeutica

(Get a free report)

CERo Therapeutics Holdings, Inc., an immunotherapy company, is focused on advancing the development of engineered T cell therapies for the treatment of cancer. The lead program in hematological malignancies targets an Eat Me signal that is upregulated on B cell and myeloid tumors. The company is based in South San Francisco, California.

About Trinity Capital

(Get a free report)

Trinity Capital Inc. is a business development company. It is a venture capital firm specializing in venture debt for growth-stage companies seeking loans and/or equipment financing. Trinity Capital Inc. was founded in 2019 and is based in Phoenix, Arizona with additional offices throughout the United States.



Receive daily news and reviews for CERo Therapeutics – Enter your email address below to receive a daily digest of the latest news and analyst ratings for CERo Therapeutics and related companies with MarketBeat.com’s FREE daily email newsletter.

Back To Top